Select Equity Group L.P. Sells 22,755 Shares of Certara, Inc. (NASDAQ:CERT)

Select Equity Group L.P. decreased its holdings in shares of Certara, Inc. (NASDAQ:CERT) by 11.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 172,488 shares of the company’s stock after selling 22,755 shares during the period. Select Equity Group L.P. owned 0.11% of Certara worth $1,837,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. raised its position in Certara by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 12,437,089 shares of the company’s stock valued at $132,455,000 after purchasing an additional 38,068 shares during the last quarter. ArrowMark Colorado Holdings LLC raised its position in Certara by 164.2% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company’s stock valued at $66,171,000 after purchasing an additional 3,861,674 shares during the last quarter. Teacher Retirement System of Texas raised its position in Certara by 13.9% during the 4th quarter. Teacher Retirement System of Texas now owns 4,557,951 shares of the company’s stock valued at $48,542,000 after purchasing an additional 557,348 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in Certara by 4.7% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,083,940 shares of the company’s stock valued at $43,494,000 after purchasing an additional 182,042 shares during the last quarter. Finally, Brown Brothers Harriman & Co. grew its holdings in shares of Certara by 63.8% during the 4th quarter. Brown Brothers Harriman & Co. now owns 3,818,613 shares of the company’s stock worth $40,668,000 after acquiring an additional 1,487,998 shares during the period. Institutional investors own 73.96% of the company’s stock.

Certara Stock Performance

Certara stock opened at $11.88 on Friday. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $1.93 billion, a P/E ratio of -59.40, a PEG ratio of 9.29 and a beta of 1.57. The stock’s 50 day moving average is $11.72 and its 200 day moving average is $11.73. Certara, Inc. has a twelve month low of $8.64 and a twelve month high of $17.76.

Certara (NASDAQ:CERT) last posted its quarterly earnings results on Monday, May 5th. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.04. The company had revenue of $106.00 million for the quarter, compared to the consensus estimate of $104.44 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The firm’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.10 EPS. On average, equities research analysts predict that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on CERT. Stephens reiterated an “overweight” rating and set a $17.00 target price on shares of Certara in a report on Thursday, February 27th. JMP Securities reiterated a “market perform” rating on shares of Certara in a report on Tuesday, May 6th. Robert W. Baird upped their target price on Certara from $9.00 to $13.00 and gave the stock a “neutral” rating in a report on Friday, April 11th. Barclays upgraded Certara from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $11.00 to $14.00 in a report on Thursday, May 8th. Finally, TD Cowen began coverage on Certara in a report on Thursday, February 27th. They set a “buy” rating and a $16.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $15.67.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.